HMN 2025: How FDA approves Monjuvi for relapsed, refractory follicular lymphoma

The U.S. Food and Drug Administration has permitted Monjuvi (tafasitamab-cxix) for the therapy of grownup sufferers with relapsed or refractory follicular lymphoma.

Monjuvi is a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody for use together with rituximab and lenalidomide to deal with sufferers with relapsed or refractory follicular lymphoma.

The approval was primarily based upon outcomes from the section 3 inMIND trial, which randomized sufferers in a double-blind method to therapy with Monjuvi (273 sufferers) or placebo (275 sufferers) together with rituximab and lenalidomide.

The trial confirmed a statistically vital and clinically significant enchancment in progression-free survival (PFS) by investigator evaluation within the Monjuvi group: 27.5% of sufferers had an occasion within the therapy arm versus 47.6% within the {control} arm.

For sufferers receiving Monjuvi together with rituximab and lenalidomide, median PFS by investigator evaluation was 22.4 months, in comparison with 13.9 months within the {control} arm (hazard ratio, 0.43). With evaluation by an unbiased overview committee, median PFS was not reached by the Monjuvi group versus 16.0 months for the {control} arm (hazard ratio, 0.41).

Serious antagonistic reactions occurred in 33% of sufferers who acquired Monjuvi together with rituximab and lenalidomide, together with severe infections in 24% of sufferers (pneumonia and COVID-19). Other severe antagonistic reactions included renal insufficiency (3.3%), second main malignancies (2.9%), and febrile neutropenia (2.6%). Fatal antagonistic reactions (COVID-19, sepsis, and adenocarcinoma) occurred in 1.5% of sufferers.

“While the preliminary responses to follicular lymphoma therapy are sometimes constructive, recurrence can turn into more and more troublesome for sufferers to handle as they navigate feelings and the following therapy steps associated to relapse,” Mitchell Smith, M.D., Ph.D., chief medical officer of the Follicular Lymphoma Foundation, stated in a press release.

“We are happy that the FDA has permitted tafasitamab, a part of a therapy mixture providing a brand new possibility for sufferers dwelling with this continual illness.”

Approval of Monjuvi was granted to Incyte.